iBio, Inc. Common Stock (IBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has a cash flow conversion efficiency ratio of -0.093x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.24 Million) by net assets ($56.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See iBio, Inc. Common Stock (IBIO) net asset quality to measure how much of total assets are equity-financed.
iBio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how iBio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check iBio, Inc. Common Stock earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
iBio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iBio, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dinamik Isi Makina Yalitim Malzemeleri Sanayi ve Ticaret AS
IS:DNISI
|
-0.013x |
|
SuperCom Ltd
F:50S
|
-0.056x |
|
SRM Entertainment, Inc. Common Stock
NASDAQ:SRM
|
0.000x |
|
Nila Spaces Limited
NSE:NILASPACES
|
-0.017x |
|
Polychem Indonesia Tbk
JK:ADMG
|
-0.015x |
|
Klotho Neurosciences, Inc.
NASDAQ:KLTO
|
-0.110x |
|
Poujoulat S.A.
PA:ALPJT
|
-0.134x |
|
Optivision Technology
TWO:3666
|
0.002x |
Annual Cash Flow Conversion Efficiency for iBio, Inc. Common Stock (2007–2025)
The table below shows the annual cash flow conversion efficiency of iBio, Inc. Common Stock from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see IBIO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $14.88 Million | $-15.30 Million | -1.028x | -18.20% |
| 2024-06-30 | $21.32 Million | $-18.55 Million | -0.870x | +56.03% |
| 2023-06-30 | $15.38 Million | $-30.44 Million | -1.979x | -232.32% |
| 2022-06-30 | $63.48 Million | $-37.80 Million | -0.595x | -115.03% |
| 2021-06-30 | $108.57 Million | $-30.06 Million | -0.277x | -17.46% |
| 2020-06-30 | $56.61 Million | $-13.35 Million | -0.236x | +95.86% |
| 2019-06-30 | $2.46 Million | $-13.97 Million | -5.688x | -582.03% |
| 2018-06-30 | $16.16 Million | $-13.48 Million | -0.834x | +43.52% |
| 2017-06-30 | $8.91 Million | $-13.16 Million | -1.477x | -339.80% |
| 2016-06-30 | $24.04 Million | $-8.07 Million | -0.336x | +20.20% |
| 2015-06-30 | $11.23 Million | $-4.72 Million | -0.421x | +37.66% |
| 2014-06-30 | $6.10 Million | $-4.12 Million | -0.675x | +29.47% |
| 2013-06-30 | $5.07 Million | $-4.85 Million | -0.957x | +1.78% |
| 2012-06-30 | $6.17 Million | $-6.01 Million | -0.974x | +96.41% |
| 2011-06-30 | $196.64K | $-5.34 Million | -27.147x | -1144.06% |
| 2010-06-30 | $1.08 Million | $-2.35 Million | -2.182x | -372.91% |
| 2009-06-30 | $4.39 Million | $-2.02 Million | -0.461x | -348.99% |
| 2008-06-30 | $-6.20 Million | $-1.15 Million | 0.185x | -5.46% |
| 2007-06-30 | $-4.33 Million | $-849.38K | 0.196x | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more